Angeles Muñoz-Sánchez

Learn More
BACKGROUND Corticosteroids have been used to treat head injuries for more than 30 years. In 1997, findings of a systematic review suggested that these drugs reduce risk of death by 1-2%. The CRASH trial--a multicentre international collaboration--aimed to confirm or refute such an effect by recruiting 20000 patients. In May, 2004, the data monitoring(More)
OBJECTIVE To ascertain the value of transcranial Doppler ultrasonography (TCD) in the first 24 hours of hospital admission in patients suffering good-grade spontaneous subarachnoid hemorrhage (SAH) in order to detect a high-risk group for symptomatic vasospasm. METHOD Forty-nine spontaneous good-grade SAH were included. The first TCD studies were carried(More)
Twenty preterm babies enrolled in a European Multicentre Trial (Curosurf 4 high vs low dose) were treated with different doses of Curosurf (Chiesi Farmaceutici, Italy). Mean gestational age was 30.3 weeks (range 26-35), and mean birthweight 1512 g (960-2560 g). Curosurf was given as a rescue therapy in babies with severe RDS between 2-72 hours after birth.(More)
BRONCHOSCOPIC OR NON-BRONCHOSCOPIC BRONCHOALVEOLAR LAVAGE (BAL) FOR DIAGNOSING PNEUMONIA IN ICU. S. Aubas, S. Bartholomee, J.P. Roustan, H. Darbas, J. du Cailar. Two BAL techniques were compared in 38 mechanically ventilated patients-with suspected pneumonia : protected non bronchoscopic BAL (Mini BAL 20 ml injected) and bronchoscopic BAL (B-BAL 2 x 50 ml(More)
a Unidad de Cuidados Neurointensivos, Sanatorio Pasteur, San Fernando del Valle de Catamarca, Argentina b Unidad de Terapia Intensiva, Hospital San Juan Bautista, San Fernando del Valle de Catamarca, Argentina c Unidad de Paciente Crítico, Clínica Universitaria de Puerto Montt, Puerto Montt, Chile d Servicio de Neurocirugía, Universidad El Bosque, Bogotá,(More)
The CRASH 2, a randomized, double-blind, controlled trial, that enrolled 20,211 adult trauma patients, has shown that the administration of tranexamic acid significantly reduces all-cause mortality and that specifically associated with severe blood loss as well. We consider it a significant therapeutic advance, because, for the first time, a drug has been(More)